Evaluation of recombinant leishmania polyprotein plus glucopyranosyl lipid a stable emulsion vaccines against sand fly-transmitted leishmania major in C57BL/6 mice

Journal of Immunology

Volumn 189, Issue 10, 2012, Pages 4832-4841

  Peters, Nathan C ^a   Bertholet, Sylvie ^b,c   Lawyer, Phillip G ^a   Charmoy, Melanie ^a   Romano, Audrey ^a   Ribeiro Gomes, Flavia L ^a   Stamper, Lisa W ^a   Sacks, David L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; GLUCOPYRANOSYL LIPID A; INTERLEUKIN 17; LEISHMANIA VACCINE; LIPID; PHOSPHORYL LIPID A; POLYPROTEIN; POLYPROTEIN KSAC; POLYPROTEIN L110F; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG DELIVERY SYSTEM; DRUG ISOLATION; DRUG SYNTHESIS; EMULSION; FEMALE; HOST PARASITE INTERACTION; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INSECT BITE; LEISHMANIA MAJOR; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PARASITE IMMUNITY; PARASITE LOAD; PARASITE TRANSMISSION; PRIORITY JOURNAL; SKIN LEISHMANIASIS; VACCINATION; VACCINE FAILURE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EMULSIONS; INTERFERON-GAMMA; INTERLEUKIN-17; LEISHMANIA MAJOR; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; LIPID A; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PSYCHODIDAE; RECOMBINANT PROTEINS;

EID: 84868554988     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201676     Document Type: Article

References (49)

1. Kaye, P., and P. Scott. 2011. Leishmaniasis: complexity at the host-pathogen interface. Nat. Rev. Microbiol. 9: 604-615.
2. Greenblatt, C. L. 1980. The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 47: 259-285.
3. Kellina, O. I. 1981. Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the U.S.S.R. Bull. Soc. Pathol. Exot. 74: 306-318.
4. Nadim, A., E. Javadian, G. Tahvildar-Bidruni, and M. Ghorbani. 1983. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull. Soc. Pathol. Exot. 76: 377-383.
5. Handman, E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14: 229-243.
6. Momeni, A. Z., and M. Aminjavaheri. 2003. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. Eur. J. Dermatol. 13: 40-43.
7. Aebischer, T., S. F. Moody, and E. Handman. 1993. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect. Immun. 61: 220-226.
8. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2: 845-858.
9. Müller, I., P. Kropf, J. A. Louis, and G. Milon. 1994. Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major. Infect. Immun. 62: 2575-2581.
10. Afonso, L. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263: 235-237.
11. Rhee, E. G., S. Mendez, J. A. Shah, C. Y. Wu, J. R. Kirman, T. N. Turon, D. F. Davey, H. Davis, D. M. Klinman, R. N. Coler, et al. 2002. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. J. Exp. Med. 195: 1565-1573.
12. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
13. Palatnik-de-Sousa, C. B., Ade. F. Barbosa, S. M. Oliveira, D. Nico, R. R. Bernardo, W. R. Santos, M. M. Rodrigues, I. Soares, and G. P. Borja-Cabrera. 2008. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine. Expert Rev. Vaccines 7: 833-851.
14. Uzonna, J. E., G. F. Späth, S. M. Beverley, and P. Scott. 2004. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172: 3793-3797.
15. Okwor, I., and J. Uzonna. 2008. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol. Res. 41: 123-136.
16. Méndez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M. A. Moga, Y. A. Skeiky, A. Campos-Neto, S. Reed, R. A. Seder, and D. Sacks. 2001. The potency and durability of DNA-and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166: 5122-5128.
17. Selvapandiyan, A., R. Dey, S. Nylen, R. Duncan, D. Sacks, and H. L. Nakhasi. 2009. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J. Immunol. 183: 1813-1820.
18. Duthie, M. S., V. S. Raman, F. M. Piazza, and S. G. Reed. 2012. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 30: 134-141.
19. Kaye, P. M., and T. Aebischer. 2011. Visceral leishmaniasis: immunology and prospects for a vaccine. Clin. Microbiol. Infect. 17: 1462-1470.
20. Costa, C. H., N. C. Peters, S. R. Maruyama, E. C. de Brito, Jr., and I. K. Santos; Working Group on Research Priorities for Development of Leishmaniasis Vaccines. 2011. Vaccines for the leishmaniases: proposals for a research agenda. PLoS Negl. Trop. Dis. 5: e943.
21. Noazin, S., A. Khamesipour, L. H. Moulton, M. Tanner, K. Nasseri, F. Modabber, I. Sharifi, E. A. Khalil, I. D. Bernal, C. M. Antunes, and P. G. Smith. 2009. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 27: 4747-4753.
22. Noazin, S., F. Modabber, A. Khamesipour, P. G. Smith, L. H. Moulton, K. Nasseri, I. Sharifi, E. A. Khalil, I. D. Bernal, C. M. Antunes, et al. 2008. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26: 6759-6767.
23. Goto, Y., A. Bhatia, V. S. Raman, H. Liang, R. Mohamath, A. F. Picone, S. E. Vidal, T. S. Vedvick, R. F. Howard, and S. G. Reed. 2011. KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin. Vaccine Immunol. 18: 1118-1124.
24. Skeiky, Y. A., R. N. Coler, M. Brannon, E. Stromberg, K. Greeson, R. T. Crane, J. R. Webb, A. Campos-Neto, and S. G. Reed. 2002. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20: 3292-3303.
25. Bertholet, S., Y. Goto, L. Carter, A. Bhatia, R. F. Howard, D. Carter, R. N. Coler, T. S. Vedvick, and S. G. Reed. 2009. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27: 7036-7045.
26. Coler, R. N., Y. Goto, L. Bogatzki, V. Raman, and S. G. Reed. 2007. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75: 4648-4654.
27. Coler, R. N., Y. A. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leish-mania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70: 4215-4225.
28. Gomes, R., C. Teixeira, F. Oliveira, P. G. Lawyer, D. E. Elnaiem, C. Meneses, Y. Goto, A. Bhatia, R. F. Howard, S. G. Reed, et al. 2012. KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. PLoS Negl. Trop. Dis. 6: e1610.
29. Chakravarty, J., S. Kumar, S. Trivedi, V. K. Rai, A. Singh, J. A. Ashman, E. M. Laughlin, R. N. Coler, S. J. Kahn, A. M. Beckmann, et al. 2011. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29: 3531-3537.
30. Llanos-Cuentas, A., W. Calderón, M. Cruz, J. A. Ashman, F. P. Alves, R. N. Coler, L. Y. Bogatzki, S. Bertholet, E. M. Laughlin, S. J. Kahn, et al. 2010. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 +MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 28: 7427-7435.
31. Nascimento, E., D. F. Fernandes, E. P. Vieira, A. Campos-Neto, J. A. Ashman, F. P. Alves, R. N. Coler, L. Y. Bogatzki, S. J. Kahn, A. M. Beckmann, et al. 2010. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 +MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28: 6581-6587.
32. Peters, N. C., N. Kimblin, N. Secundino, S. Kamhawi, P. Lawyer, and D. L. Sacks. 2009. Vector transmission of leishmania abrogates vaccine-induced protective immunity. PLoS Pathog. 5: e1000484.
33. Stamper, L. W., R. L. Patrick, M. P. Fay, P. G. Lawyer, D. E. Elnaiem, N. Secundino, A. Debrabant, D. L. Sacks, and N. C. Peters. 2011. Infection parameters in the sand fly vector that predict transmission of Leishmania major. PLoS Negl. Trop. Dis. 5: e1288.
34. Sacks, D. L., S. Hieny, and A. Sher. 1985. Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes. J. Immunol. 135: 564-569.
35. Peters, N. C., J. G. Egen, N. Secundino, A. Debrabant, N. Kimblin, S. Kamhawi, P. Lawyer, M. P. Fay, R. N. Germain, and D. Sacks. 2008. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321: 970-974.
36. Ribeiro-Gomes, F. L., N. C. Peters, A. Debrabant, and D. L. Sacks. 2012. Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-leishmania response. PLoS Pathog. 8: e1002536.
37. De Trez, C., S. Magez, S. Akira, B. Ryffel, Y. Carlier, and E. Muraille. 2009. iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. PLoS Pathog. 5: e1000494.
38. Wu, W., L. Huang, and S. Mendez. 2010. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur. J. Immunol. 40: 2517-2527.
39. Lopez Kostka, S., S. Dinges, K. Griewank, Y. Iwakura, M. C. Udey, and E. von Stebut. 2009. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J. Immunol. 182: 3039-3046.
40. Nembrini, C., B. J. Marsland, and M. Kopf. 2009. IL-17-producing T cells in lung immunity and inflammation. J. Allergy Clin. Immunol. 123: 986-994; quiz 995-986.
41. Kimblin, N., N. Peters, A. Debrabant, N. Secundino, J. Egen, P. Lawyer, M. P. Fay, S. Kamhawi, and D. Sacks. 2008. Quantification of the infectious dose of Leishmania major transmitted to the skin by single sand flies. Proc. Natl. Acad. Sci. USA 105: 10125-10130.
42. Peters, N. C., and D. L. Sacks. 2009. The impact of vector-mediated neutrophil recruitment on cutaneous leishmaniasis. Cell. Microbiol. 11: 1290-1296.
43. Rogers, M. E., O. V. Sizova, M. A. Ferguson, A. V. Nikolaev, and P. A. Bates. 2006. Synthetic glycovaccine protects against the bite of leishmania-infected sand flies. J. Infect. Dis. 194: 512-518.
44. Gradoni, L., V. Foglia Manzillo, A. Pagano, D. Piantedosi, R. De Luna, M. Gramiccia, A. Scalone, T. Di Muccio, and G. Oliva. 2005. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leish-mania infantum infection and to prevent disease progression in infected animals. Vaccine 23: 5245-5251.
45. Trigo, J., M. Abbehusen, E. M. Netto, M. Nakatani, G. Pedral-Sampaio, R. S. de Jesus, Y. Goto, J. Guderian, R. F. Howard, and S. G. Reed. 2010. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 28: 3333-3340.
46. Miret, J., E. Nascimento, W. Sampaio, J. C. França, R. T. Fujiwara, A. Vale, E. S. Dias, E. Vieira, R. T. da Costa, W. Mayrink, et al. 2008. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 26: 1585-1594.
47. Kébaïer, C., J. E. Uzonna, S. M. Beverley, and P. Scott. 2006. Immunization with persistent attenuated Delta lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice. Infect. Immun. 74: 777-780.
48. Nylén, S., A. Khamesipour, A. Mohammadi, R. Jafari-Shakib, L. Eidsmo, S. Noazin, F. Modabber, and H. Akuffo. 2006. Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited. Vaccine 24: 6944-6954.
49. Okwor, I., S. Kuriakose, and J. Uzonna. 2010. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge. Vaccine 28: 5451-5457.